Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Debt (2020 - 2025)

Zevra Therapeutics' Non-Current Debt history spans 8 years, with the latest figure at $61.9 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 4.07% year-over-year to $61.9 million; the TTM value through Dec 2025 reached $61.9 million, up 4.07%, while the annual FY2025 figure was $61.9 million, 4.07% up from the prior year.
  • Non-Current Debt reached $61.9 million in Q4 2025 per ZVRA's latest filing, up from $61.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $61.9 million in Q4 2025 to a low of $98000.0 in Q1 2021.
  • Average Non-Current Debt over 5 years is $38.0 million, with a median of $58.3 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: soared 1074.58% in 2024, then increased 4.05% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $98000.0 in 2021, then skyrocketed by 12961.22% to $12.8 million in 2022, then tumbled by 60.42% to $5.1 million in 2023, then skyrocketed by 1074.58% to $59.5 million in 2024, then grew by 4.07% to $61.9 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Non-Current Debt are $61.9 million (Q4 2025), $61.3 million (Q3 2025), and $60.7 million (Q2 2025).